Atlas Venture Announces $400 Million Third Opportunity Fund

Audio By Carbonatix

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 4, 2025--

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its third Opportunity Fund, raising $400 million in an oversubscribed fundraise. Atlas Venture Opportunity Fund III equips Atlas to continue providing longitudinal capital to its portfolio companies as they raise subsequent financings and advance therapeutic programs. The raise comes on the heels of Atlas’ $450 million Fund XIV, its latest early stage vehicle which closed in December 2024.

"We’ve been encouraged by the incredible progress made across our portfolio, despite the array of challenges faced by biotechs in the current environment. We are thrilled to be in a position to invest Opportunity Fund III into this exceptional cohort of companies," said the Atlas partnership in a joint statement. "Opportunity Fund III reinforces our commitment to raising funds tailored in size and strategy to our bespoke investment approach. We are grateful for the support of our longstanding limited partners in our pursuit of building biotechs that can develop transformative therapeutics for patients."

Atlas' two-fund model is powered by dedicated pools of early stage and growth capital for Atlas to invest in portfolio companies with promising therapeutic programs and pipelines. Beginning with seed and Series A investments from our early-stage funds, the Atlas investment team collaborates with dedicated and expert entrepreneurs-in-residence to form and incubate new biotech companies around promising science sourced from around the globe. With Opportunity Fund III in place, Atlas will continue investing meaningfully in select later stage private and public financings of existing portfolio companies, paired with ongoing strategic involvement.

Atlas Venture has a long history of building biotechnology companies spanning more than three decades. Atlas' experienced investment team work seamlessly across both the firm's early stage and opportunity funds to maximize the potential for successful therapeutic development and value recognition. The general partners in Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes. Jean-François Formela and David Grayzel continue as partners at Atlas Venture contributing their experience across the firm.

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 30 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250904269555/en/

CONTACT: Media Contact:

Kristen Margeson

Vice President of Investor Relations and Marketing

Atlas Venture

857-201-2700

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH FINANCE HEALTH PROFESSIONAL SERVICES

SOURCE: Atlas Venture

Copyright Business Wire 2025.

PUB: 09/04/2025 07:00 AM/DISC: 09/04/2025 07:00 AM

http://www.businesswire.com/news/home/20250904269555/en